Latest Articles and Analysis

Congenital syphilis has risen for 12 consecutive years — not because we lack a cure, but because the only approved treatment is in shortage, coverage is shrinking in the hardest-hit states, and immigration fear is keeping pregnant people away from the prenatal care where screening happens. The tools exist. The system keeps failing to deliver them.

Formulary cuts, fibrosis staging requirements making a comeback, and the near-disappearance of HCV charitable assistance programs — CANN's Q3 2026 HIV/HCV Co-Infection Watch maps a deteriorating access landscape for people living with HIV/HCV co-infection.

Congress has introduced the most ambitious federal hepatitis C elimination bill in a generation — $9.8 billion, no cost-sharing, and a delivery investment long overdue. The procurement model at its center could undermine the access it promises.

Prescription Drug Affordability Boards are operating in states across the country, but their primary tool — Upper Payment Limits — threatens pharmacies, Medicaid programs, and the patients they're supposed to help. The evidence is mounting that UPLs are the wrong solution to a real problem.

The Centers for Disease Control and Prevention (CDC) released its National HIV Prevention and Care Objectives: 2026 Update on May 18, 2026, presenting the most recent national picture of the U.S. HIV...

On March 6, 2026, the Iowa Department of Health and Human Services filed a nine-page complaint in Polk County District Court alleging that NuCara Specialty Pharmacy failed to remit more than $22...

The HIV/HCV Co-Infection Watch is a project of the Community Access National Network (CANN) designed to research, monitor, and report on HIV and Hepatitis C (HCV) co-infection in the United States....

States are rationing HIV medications through prior auth and formulary cuts to solve ADAP budget crises — a strategy that costs more, drives resistance, and concentrates harm on the most vulnerable.

ADAPs achieve 87% viral suppression but face funding crisis as multiple policies erode 340B rebates.

Q1 2026 Watch: HCV/HIV co-infection treatment access under evolving federal and state policies.

Florida ADAP cuts eligibility from 400% to 130% FPL, threatening 16,000 PLWHA.

Enhanced ACA subsidies expired Jan 1; Senate framework proposes two-year extension with restrictions.

2025 healthcare crises result from policy choices as ACA subsidies expire, HIV care deteriorates, and state pricing experiments proliferate.

Federal policy changes including Medicaid work requirements and ADAP eligibility restrictions threaten access to HIV medications.

Q4 2025 Watch monitoring HCV treatment access and federal initiatives including Cure Hepatitis C Act.

Q3 2025 Watch: critical analysis including Cure Hepatitis C Act proposing subscription treatment models.

340B program expansion drains billions from state Medicaid budgets while failing to deliver promised drug cost savings.

Impending HIV care crisis results from Medicaid work requirements, federal funding cuts, and healthcare system fragmentation.

Q2 2025 Watch monitoring HCV and HIV treatment access through ADAPs, Medicaid, and federal assistance.

Proposed Medicaid cuts and work requirements threaten coverage for millions including people living with HIV.